Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital ...
Wedbush boosted their FY2029 earnings estimates for shares of Rezolute in a report released on Thursday, February 13th.
Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Rezolute in a research report issued on ...
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.
The primary focus of Rezolute's pipeline is ersodetug, which is currently undergoing Phase 3 trials for both CHI and tumor-induced HI. The sunRIZE trial for CHI has been actively enrolling patients ...
The primary focus of Rezolute's pipeline is ersodetug, which is currently undergoing Phase 3 trials for both CHI and tumor-induced HI. The sunRIZE trial for CHI has been actively enrolling ...
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...
Hosted on MSN6d
Rezolute’s Strategic Advances in Rare Disease TherapiesRezolute, Inc. ( ($RZLT) ) has released its Q2 earnings. Here is a breakdown of the information Rezolute, Inc. presented to its investors.
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback